Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07558733 · ClinicalTrials.gov registry record · Phase 1
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
A Phase 1 study, sponsored by Faeth Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT07558733 is a Phase 1 study that is actively recruiting participants, run by Faeth Therapeutics. The registered enrollment target is 32 participants.
The verdict
NCT07558733, a Phase 1 study, is actively recruiting participants, sponsored by Faeth Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.
Interventions
- DRUG Fulvestrant
- DRUG Sapanisertib
- DRUG Serabelisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-04-22 |
| Est. Completion | 2033-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07558733
The ClinicalTrials.gov registry entry for NCT07558733 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Faeth Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fulvestrant is the first listed.
NCT07558733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07558733 about?
NCT07558733 is a clinical study titled "Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer". The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.
What is the current status of trial NCT07558733?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-04-22. Estimated completion is 2033-05.
What interventions are being tested in trial NCT07558733?
The interventions under investigation include: Fulvestrant (DRUG), Sapanisertib (DRUG), Serabelisib (DRUG).
Who is sponsoring clinical trial NCT07558733?
This trial is sponsored by Faeth Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.